Rigel Pharmaceuticals
RIGL
162 hedge funds and large institutions have $365M invested in Rigel Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 43 increasing their positions, 55 reducing their positions, and 26 closing their positions.
0.02% more ownership
Funds ownership: 8.05% → 8.07% (+0.02%)
0% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 26
1% less funds holding
Funds holding: 163 → 162 (-1)
9% less call options, than puts
Call options by funds: $1.08M | Put options by funds: $1.19M
22% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 55
27% less capital invested
Capital invested by funds: $500M → $365M (-$134M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$9.11M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$5.61M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$3.85M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$3.59M |
| 5 |
Walleye Capital
New York
|
+$2.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Ion Asset Management
Herzliya,
Israel
|
-$12.1M |
| 2 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$7.54M |
| 3 |
Two Sigma Advisers
New York
|
-$3.77M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.93M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$2.41M |
RIGL Hedge Fund Activity: Q4 2021 in Review
162 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2021, worth a combined $365M — down 27% from $500M a quarter earlier.
Fund positioning in RIGL was balanced in Q4 2021: 26 funds opened new positions, 26 closed out, 43 added to existing stakes and 55 trimmed.
The largest buyer was Great Point Partners, adding an estimated $9.11M. The largest seller was Ion Asset Management, exiting entirely with an estimated $12.1M sold.
- 162 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2021, down from 163 in Q3 2021.
- Funds reported $365M of Rigel Pharmaceuticals stock for Q4 2021, down 27% quarter-over-quarter.
- 26 funds opened new Rigel Pharmaceuticals positions in Q4 2021 and 26 closed out, a net change of 0 holders.
- The largest Rigel Pharmaceuticals buyer in Q4 2021 was Great Point Partners, an estimated $9.11M added.
- The largest Rigel Pharmaceuticals seller in Q4 2021 was Ion Asset Management, an estimated $12.1M sold.
Based on aggregated 13F filings for Q4 2021.